
usd may pm et
summari danah corpor design manufactur market profession medic industri
commerci product servic global
price-to-earnings oper ep
risk assess reflect modest growth prospect
compani market good corpor
leadership solid balanc sheet compani
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
origin anticip growth
howev headwind
overcom tailwind opinion
expect dhr sale grow
includ impact late-march
billion acquisit biopharma busi
call cytiva sale
growth biopharma busi
acceler dhr core growth
respect posit view dhr
acquisit busi
immens size acquisit could prove
challeng
drive higher revenu ep growth
invest higher-technolog
busi new geograph market
boost dhr growth potenti
spin-off weak margin
revenu
complet divest decemb
expect continu ebitda margin
improv driven dhr recent portfolio
manag activ look ebitda
margin
find share trade
earn estim near fair valu
high recur revenu strong balanc
sheet support like continu
support abil make acquisit
key compon growth recent
year find manag
experienc make integr
acquisit compani suffer
margin degrad recent year
taken mani charg relat acquisit
risk recommend target price
includ failur integr acquisit
stronger-than-expect advers impact
slowdown
biopharmaceut develop
target price base
ep estim
averag forward fy multipl
increas exposur high
margin product substanti aid
acquisit
expect busi
accret ep
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview danah corpor design manufactur market profession
medic industri commerci product servic dhr research develop manufactur
sale distribut servic administr facil locat countri
dhr sale origin outsid total sale come western europ
high-growth market dhr busi broken three segment life scienc
revenu diagnost environment appli solut spun
dental segment repres revenu
life scienc segment offer broad rang research tool scientist use studi basic
build block life includ gene protein metabolit cell order understand caus
diseas identifi new therapi test new drug vaccin segment pall
corpor pall busi also lead provid filtrat separ purif technolog
biopharmaceut food beverag medic aerospac microelectron gener industri
sector sale segment geograph destin north america
europ develop market high-growth market
acquir biotechnolog busi ge biopharma part
life scienc segment name cytiva cytiva busi lead provid
instrument softwar consum help biopharmaceut industri identifi modifi
gene cell protein better understand dynam diseas pathway design
develop manufactur therapi intend target diseas busi offer product
support custom across biopharmaceut valu chain earliest stage drug
discoveri research product process develop clinic trial therapi manufactur
diagnost segment offer analyt instrument reagent consum softwar servic
hospit physician offic refer laboratori critic care set use diagnos
diseas make treatment decis sale segment geograph destin
north america western europ develop market high-growth market
compani environment appli solut segment offer product servic help protect
import resourc keep global food water suppli safe sale segment
geograph destin north america western europ develop market
high-growth market
corpor strategi compani seek expand revenu combin intern growth
acquisit compani histori success acquisit expect compani
remain acquisit long balanc sheet cash flow support activ
impact major develop gener electr agre sell biotechnolog busi ge
biopharma billion cash februari elimin major competitor
strong track record buy integr busi immens size
acquisit could prove challeng march complet acquisit
oper stand-alon compani call cytiva dhr life scienc segment ge
biopharma busi gener revenu approxim billion expect acquisit
accret adjust earn
septemb spun-off dental busi revenu name
envista trade publicli ticker nyse divest remain ownership
april close billion acquisit supplier custom nucleic
acid acquir ten busi total consider million cash net cash
acquir acquir cepheid lead global molecular diagnost compani total
purchas price approxim billion seven busi total consider
million cash net cash acquir
august acquir pall corp pll billion conjunct purchas
announc plan split two separ publicly-trad compani first maintain
name would combin pll life scienc filtrat busi second name
would includ industri busi includ test measur spun
sharehold juli sharehold receiv one share share
financi trend revenu grew year-over-year billion reflect
three-year compound annual growth rate compound-annual-growth-rate revenu growth continu oper
dhr five-year ep compound-annual-growth-rate year end decemb
free cash flow defin cash flow oper less capit expenditur remain
steadi last sever year decreas billion addit compani
low debt balanc decemb net debt total capit ge biopharma
acquisit expect dhr debt leverag higher report result
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold opinion share danah corpor
lift target base multipl
ep estim multipl three-year
averag forward multipl compani increas exposur
attract market ep vs lower estim
lower ep reflect impact
recent equiti offer associ in-progress ge biopharma acquisit
lift ep sale increas organ
billion organ revenu growth life scienc segment
diagnost dental environment despit concern around
china trade tension slowdown chines economi achiev
ninth consecut quarter double-digit growth china growth across
four segment manag appear much concern
stabil european market /kevin huang cfa
pm et cfra reiter hold opinion share danah corpor
lift price target base multipl
ep estim forward
price-to-earnings averag reflect strong momentum posit view today
news gener electr ge agre today sell biotechnolog
busi ge biopharma billion cash
elimin major competitor strong track record
buy integr busi immens size acquisit could
prove challeng ge biopharma lead provid instrument
consum softwar support research discoveri process
develop manufactur workflow biopharmaceut drug
anticip gener billion sale expect
transact close acquir busi
stand-alon oper compani life scienc segment /kevin
pm et cfra keep hold opinion share danah corpor
lift target price base
multipl ep estim ep vs
line consensu expect updat estim reflect
expect lower ep
ep expect core revenu growth
includ recent acquir cytiva busi flat
headwind overcom tailwind april dhr busi
experienc diverg trend certain area saw elev demand
diagnost bioprocess other saw much
weaker-than-norm demand instrument-ori busi cater
academ research lab addit ceo thoma joyc announc upcom
retir expect incom ceo rainer blair current evp life
scienc busi similar manag style strateg focu
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim increas multipl
reflect dhr increas exposur high margin product
pend acquisit significantli lower-than-expect
financ cost said acquisit ep vs came
consensu lower ep estim
initi ep sale increas organ
billion dhr high-growth market grew high
single-digit western europ sale grew mid-single-digit
continu expect busi acquir
expect acquisit contribut ep satisfi
regulatori requir soon divest certain life scienc busi
provid annual revenu approxim million /kevin huang
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim forward multipl
reflect compani increas exposur attract market ep
vs estim adjust ep
ep sale increas
organ billion organ revenu growth life scienc
segment diagnost environment believ
share trade slightli today compani weaker-than-expect
guidanc core revenu growth remind complet
ipo dental busi envista nr mid-septemb
end own also anticip
acquisit complet rather ge
biopharma busi call cytiva becom part /kevin
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim multipl
significantli histor forward multipl compani
increas exposur attract market ep vs
consensu estim rais ep
ep estim sale increas organ
billion organ revenu growth life scienc segment
diagnost dental environment spite
concern slow econom growth china manag confid
underli condit sale china grew year-over-year
quarter addit upcom ipo dental busi
anticip merger aim
close remain track dental busi call envista /kevin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
